LobbyingOvarian Cancer Research Fund Alliance lobbying by quarter
Ovarian Cancer Research Fund Alliance's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Health Issues.
Ovarian Cancer Research Fund Alliance
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $0 | 1 |
| Q1 2023 | $0 | 1 |
| Q2 2023 | $0 | 1 |
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$0 · 15 reports
- Health issues$0 · 15 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Centers For Disease Control & Prevention (CDC)15 reports
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseOvarian Cancer Research Fund Alliance | $0 | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/07for Q2 | In-house | Under $5,000 |
| 06/03for Q1 | In-house | Under $5,000 |
| 02/05for Q4 2025 | In-house | Under $5,000 |
| 25/11/06for Q3 2025 | In-house | Under $5,000 |
| 25/08/05for Q2 2025 | In-house | Under $5,000 |
| 25/05/05for Q1 2025 | In-house | Under $5,000 |
| 25/02/04for Q4 2024 | In-house | Under $5,000 |
| 24/11/12for Q3 2024 | In-house | Under $5,000 |
| 24/08/20for Q2 2024 | In-house | Under $5,000 |
| 24/05/07for Q1 2024 | In-house | Under $5,000 |
| 24/02/05for Q4 2023 | In-house | Under $5,000 |
| 23/11/20for Q3 2023 | In-house | Under $5,000 |
| 23/08/28for Q2 2023 | In-house | Under $5,000 |
| 23/05/30for Q1 2023 | In-house | Under $5,000 |
| 23/02/06for Q4 2022 | In-house | Under $5,000 |